This article is more than 5 years old. Information may no longer be current.
Psoriasis registry enrolls 3,000th patient
The National Psoriasis Foundation recently announced that the Corrona Psoriasis Registry, a joint collaboration between the foundation and Corrona, LLC, has enrolled its 3,000th patient.
The Corrona Psoriasis Registry is the largest, independent U.S. registry of psoriasis patients and was launched 2 years ago to compare the safety and effectiveness of FDA-approved psoriasis therapies. It has registered psoriasis patients from 128 sites across 33 states, according to a news release.
There have been more than 230 dermatology health care providers who have contributed data to the registry, and the registry data has been used in 18 research posters presented at medical conferences, according to the release.
“As an independent registry, the Corrona registry is well positioned to answer critical research questions facing psoriasis patients on the risk-benefit profile of newly approved drugs, empowering the psoriasis patient community,” Mark Lebwohl, MD, professor and chairman, Kimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai, chairman emeritus of the National Psoriasis Foundation medical board, and scientific co-director of the registry, stated in the release.
Instead of the traditional model where each individual pharmaceutical company sponsors its own phase 4 clinical study to investigate the post-approval safety of its drug, the Corrona registry uses a collaborative model “which integrates the post-approval safety study commitments of multiple companies into a single, large-scale registry with multiple drug treatment cohorts,” according to the release.
Advantages of the collaborative model include streamlining the workflow for investigators and patients into a single protocol and set of patient questionnaires, according to the release.
Reference: www.psoriasis.org